Availability Archives - Page 4 of 5

Vaccae

modelling the population-level health and economic impacts of introducing Vaccae vaccination to inform policy-makers in China

Is neglect of self-clearance biasing TB vaccine impact estimates?

exploring the inclusion of self-clearance in models of tuberculosis affects the estimates of vaccine impact in China and India

The full value of vaccine assessments concept—current opportunities and recommendations

Building on the success of the recent applications of the FVVA framework, we see important new opportunities to maximize the future utility of FVVAs to country and global stakeholders and provide a proof-of-concept for analyses in other areas of disease control and prevention.

Mapping the existing body of knowledge on new and repurposed TB vaccine implementation: A scoping review

BCG revaccination, Hypothetical vaccines, M72/AS01e

By synthesizing the existing body of knowledge, this review offers comprehensive insights into the current state of research on implementation of these TB adults and adolescent vaccines. Offering insights into key dimensions: (1) epidemiological impact, (2) costing, cost-effectiveness, and/or economic impact, (3) acceptability, and the (4) feasibility of implementation; this includes implementation strategies of target populations, and health system capabilities.

An investment case for new tuberculosis vaccines

2022

This document summarizes the results of the WHO-commissioned full value proposition for new TB vaccines. It is for use by national and global decision-makers involved in vaccine development and implementation.

TPTVaxx

Planned

Vaccines will be introduced in contexts where TPT already exists. Exploration of possible study designs, expected effectiveness, feasibility of integrated approaches is key.

Evidence considerations for vaccine policy development for tuberculosis vaccines intended for adults and adolescents

The ECVP facilitates early engagement and alignment across the stakeholders involved in vaccine development and those responsible for vaccine regulatory, policy, funding and country introduction decisions. This framework aims to anticipate and collectively delineate the clinical trial, observational, and other data likely to be required by global and national policymakers, and to do so when most valuable – during development of the late-stage clinical plan, including the design of the pivotal licensure trial.

Conducting market analyses for new tuberculosis vaccines for adolescents and adults: A summary of one approach applied to M72/AS01E

A summary report of the methodology used in the MM Global Health Consulting (MMGH) market anlysis and the high-level findings and recommendations.

A global framework to prepare for country introduction of new TB vaccines for adults and adolescents

New vaccines for the prevention of TB disease in adolescents and adults could become available in the next 3-5 years. WHO has therefore developed a Global Framework to prepare for Country Introduction of New TB Vaccines for Adults and Adolescents which aims to guide countries and global stakeholders in preparing for the introduction and scale-up in countries. This framework has been drafted in collaboration with a WHO Expert Advisory Group and in consultation with other stakeholders, and describes critical activities to prepare for introduction decision-making and subsequent implementation and impact of new TB vaccines for adults and adolescents.

Preferred product characteristics for new tuberculosis vaccine

2018